STAT+: Insmed’s lung disease drug approved in the U.S.
Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be a multibillion-dollar product.
Previous Post
One Month at the World’s Largest Eye Hospital
Next Post
Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago